Wedbush Securities’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Wedbush Securities’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-615	Closed	-$150K	–	1003
2020 Q3	$150K	Sell	615 -126	-17%	-$39.2K	0.01%	793
2020 Q2	$213K	Buy	741 +221	+43%	+$65.1K	0.02%	754
2020 Q1	$106K	Buy	520 +134	+35%	+$42.7K	0.01%	765
2019 Q4	$173K	Sell	386 -5	-1%	-$1.77K	0.02%	884
2019 Q3	$120K	Sell	391 -19	-5%	-$6.17K	0.01%	884
2019 Q2	$130K	Sell	410 -16	-4%	-$5.54K	0.01%	877
2019 Q1	$179K	Buy	+426	New	+$171K	0.02%	801
2018 Q2	–	Sell	-645	Closed	-$191K	–	914
2018 Q1	$191K	Buy	+645	New	+$191K	0.02%	696
2017 Q4	–	Sell	-345	Closed	-$114K	–	909
2017 Q3	$114K	Buy	+345	New	+$94K	0.01%	770
2016 Q1	–	Sell	-38	Closed	-$25K	–	808
2015 Q4	$25K	Hold	38	–	–	﹤0.01%	709
2015 Q3	$18K	Buy	38 +7	+23%	+$3.71K	﹤0.01%	701
2015 Q2	$18K	Buy	+31	New	+$85.8K	﹤0.01%	711

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wedbush Securities's EIGR Position: Q4 2020 in Review

Wedbush Securities sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2020, closing a stake of 615 shares — an estimated $150K sold.

Wedbush Securities first reported a position in EIGR in Q2 2015 and held it in 12 quarters. The position peaked at $213K in Q2 2020. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2020.

Wedbush Securities reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Wedbush Securities sold 615 Eiger BioPharmaceuticals, Inc. shares in Q4 2020, an estimated $150K.
Wedbush Securities first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2015 and held it in 12 quarters.
Wedbush Securities's Eiger BioPharmaceuticals, Inc. position peaked at $213K in Q2 2020.
91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.